These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29724189)

  • 1. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.
    Rogasch JMM; Hundsdoerfer P; Hofheinz F; Wedel F; Schatka I; Amthauer H; Furth C
    BMC Cancer; 2018 May; 18(1):521. PubMed ID: 29724189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.
    Song MK; Chung JS; Lee JJ; Jeong SY; Lee SM; Hong JS; Chong A; Moon JH; Kim JH; Lee SM; Kim SJ; Shin HJ
    Cancer Sci; 2013 Dec; 104(12):1656-61. PubMed ID: 24033666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of baseline and interim [
    Yadgarov MY; Dunaykin MM; Shestopalov GI; Kailash C; Kireeva ED; Myakova NV; Likar YN
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1955-1964. PubMed ID: 38351389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
    van Heek L; Stuka C; Kaul H; Müller H; Mettler J; Hitz F; Baues C; Fuchs M; Borchmann P; Engert A; Dietlein M; Voltin CA; Kobe C
    BMC Cancer; 2022 Jun; 22(1):672. PubMed ID: 35717166
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Georgi TW; Kluge R; Kurch L; Chavdarova L; Hasenclever D; Stoevesandt D; Pelz T; Landman-Parker J; Wallace WH; Karlen J; Fernández-Teijeiro A; Cepelova M; Fosså A; Balwierz W; Attarbaschi A; Ammann RA; Pears J; Hraskova A; Uyttebroeck A; Beishuizen A; Dieckmann K; Leblanc T; Daw S; Baumann J; Körholz D; Sabri O; Mauz-Körholz C
    J Nucl Med; 2018 Oct; 59(10):1524-1530. PubMed ID: 29653979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
    Chang S; Kim SJ
    Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
    van Heek L; Weindler J; Gorniak C; Kaul H; Müller H; Mettler J; Baues C; Fuchs M; Borchmann P; Ferdinandus J; Dietlein M; Voltin CA; Kobe C; Roth KS
    Eur J Haematol; 2023 Dec; 111(6):881-887. PubMed ID: 37644732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different
    El-Hennawy G; Moustafa H; Omar W; Elkinaai N; Kamel A; Zaki I; Farid N; El-Kholy E
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28605. PubMed ID: 32706520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in
    Higuchi T; Fujimoto Y; Ozawa H; Bun A; Fukui R; Miyagawa Y; Imamura M; Kitajima K; Yamakado K; Miyoshi Y
    Ann Surg Oncol; 2019 Jul; 26(7):2175-2183. PubMed ID: 30941655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semiquantitative analysis of interim
    Ribeiro T; Marques A; Ferreira G; Castro C; Tavares M; Espírito-Santo A; Moreira C; Mariz J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(5):281-286. PubMed ID: 34425968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score.
    Milgrom SA; Dong W; Akhtari M; Smith GL; Pinnix CC; Mawlawi O; Rohren E; Garg N; Chuang H; Yehia ZA; Reddy JP; Gunther JR; Khoury JD; Suki T; Osborne EM; Oki Y; Fanale M; Dabaja BS
    Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):333-338. PubMed ID: 28068241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumor burden and therapy outcome in patients with Hodgkin lymphoma.
    Lawal IO; Nyakale NE; Harry LM; Modiselle MR; Ankrah AO; Msomi AP; Mokgoro NP; Boshomane TG; de Wiele CV; Sathekge MM
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):2025-2033. PubMed ID: 28660348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.
    Tseng D; Rachakonda LP; Su Z; Advani R; Horning S; Hoppe RT; Quon A; Graves EE; Loo BW; Tran PT
    Radiat Oncol; 2012 Jan; 7():5. PubMed ID: 22260710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Hassan A; Siddique M; Bashir H; Riaz S; Wali R; Mahreen A; Nawaz MK
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1198-1206. PubMed ID: 28229191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031.
    Milgrom SA; Kim J; Chirindel A; Kim J; Pei Q; Chen L; Buxton A; Kessel S; Leal J; McCarten KM; Hoppe BS; Wolden SL; Schwartz CL; Friedman DL; Kelly KM; Cho SY
    Pediatr Blood Cancer; 2021 Sep; 68(9):e29212. PubMed ID: 34245210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including
    Latifoltojar A; Punwani S; Lopes A; Humphries PD; Klusmann M; Menezes LJ; Daw S; Shankar A; Neriman D; Fitzke H; Clifton-Hadley L; Smith P; Taylor SA
    Eur Radiol; 2019 Jan; 29(1):202-212. PubMed ID: 29948084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.